Do We Get Samples of the Report?

Yes, you will receive a sample copy of the market research report from the sales team when you put a query to us. The sample report is free and offers a brief view of the report and information on data available before you purchase the full-fledged report. Also, we will provide a demo sample for any oncoming study.

How to Buy a Market Report?

Select the report you wish to purchase and proceed to buy it by making an online payment. We use a secured gateway for payment transfers and do not share your financial information with any unconcerned third party.

In Which Format Will I Get the Report?

The report will be delivered in spreadsheet and PDF format. In some cases, PPT formats could be available as well.

In How Much Time I will Get the Report After Purchase?

After confirmation of the payment, you will receive the electronic format of the report at your registered email address in (mention the timeline for the delivery). If you buy a report over a holiday or weekend, we will process the request the next working day.

How Can I Get the Report Customized?

Market studies and reports already contain important data and are ready for distribution to the purchaser. However, if there is any particular query, addition, or customization you require, then contact us on our email id or phone. We will look to accommodate your request and see what can be done at the earliest. The research team will design the report accordingly and discuss the solutions beforehand with you.

How Much Will It Cost to Get a Report Customized?

The price of the customized report will be conveyed to you by our team after we agree on the deliverable. A delivery timeline will be set so that you get the report within the expected date. Any requests for customizations after selling the report will be handled by a separate department and the prices for the same mentioned upfront.

Can I Buy Only a Particular Segment of the Study?

While usually such a request is not accommodated as any market research report is wholesome and the cost of the report is for overall contents, in special cases, we may be able to sell select segments of the report based on your requirements.

Is There Any Available Discount?

Our team will love to support academicians, start-ups, students, and others with consulting and research. Thus, our pricing plan is based on keeping these interests in mind and is already affordable. However, we may have discounts available for particular customer types and reports. So, contact us for more information.

Which Services Are Complimentary Before Purchasing the Report?

We have consumer-centric reports and offer several facilities before selling. You will get a free review and sample report, talk to our customer care team for any additions to be done and meet special requirements, and interact with our analysts for deeper understanding.

Will I Receive a Bill or Invoice for the Report Purchased?

Yes, you will get an invoice for the purchase you made. The invoice will be sent to you electronically on your registered email id.

What If I am Unable to Find the Report in the Catalog?

We have a vast database of market reports and studies and there are a few which may not have been uploaded yet. If you are unable to find the one you want, then get in touch with our sales team by phone or email and we will connect with you for assistance.

How Often Are the Existing Studies Updated?

Not every study is the same. Thus, the update for reports will depend on the ongoing research and changes if any to be incorporated in the document or not.

What If the Report Does Not Contain the Information I Want?

The market research reports are constructed keeping in mind the industry trends, nature of the study, and required inputs. But if you want something more than what is stated in the report, we can help you out with further research if possible. Contact us right away, and we will do the needful to aid you.

Is the Payment Refundable?

Once the payment is done, it is non-refundable because as per the standard policy, the utility of the reports is based on knowledge sharing, and thus, a refund is not possible to make after we have issued you obtain the study. To avoid the hassle, we have a detailed view of the report and its ideas through a sample report.

What If the Payment Fails?

If the payment fails then be assured that you shall receive the money back to the source payment mode from the payment gateway. Aarkstore is not responsible for any loss of payment in the process.

Can I Avail the Report of a Particular Country/Region?

Yes, we can provide a report or segment related to a particular region or geography if we have that feature available for the document.

Do You Offer Support After Purchase?

Yes, we are here to solve any queries you may have for the report from our analyst till a given timeframe. To understand more about this, get in touch with us.

Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Pipeline Review, H2 2019

DESCRIPTION

TABLE OF CONTENTS

RELATED REPORTS

SAMPLE REQUEST

REVIEWS

DESCRIPTION

Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Pipeline Review, H2 2019

Summary

latest Pharmaceutical and Healthcare disease pipeline guide Fibrodysplasia Ossificans Progressiva - Pipeline Review, H2 2019, provides an overview of the Fibrodysplasia Ossificans Progressiva (Musculoskeletal Disorders) pipeline landscape.

Fibrodysplasia ossificans progressiva (FOP) is a disorder in which muscle tissue and connective tissue such as tendons and ligaments are gradually replaced by bone (ossified), forming bone outside that constrains movement. Symptoms swellings in fibrous tissue, pain, fever, muscle ossification and restricted movement of joints. Treatment includes surgery and medications to help relieve symptoms of FOP, such as pain and inflammation.

Report Highlights

Pharmaceutical and Healthcare latest pipeline guide Fibrodysplasia Ossificans Progressiva - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Fibrodysplasia Ossificans Progressiva (Musculoskeletal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Fibrodysplasia Ossificans Progressiva (Musculoskeletal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 4, 5 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.

Fibrodysplasia Ossificans Progressiva (Musculoskeletal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Fibrodysplasia Ossificans Progressiva (Musculoskeletal Disorders).
- The pipeline guide reviews pipeline therapeutics for Fibrodysplasia Ossificans Progressiva (Musculoskeletal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Fibrodysplasia Ossificans Progressiva (Musculoskeletal Disorders) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Fibrodysplasia Ossificans Progressiva (Musculoskeletal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Fibrodysplasia Ossificans Progressiva (Musculoskeletal Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Fibrodysplasia Ossificans Progressiva (Musculoskeletal Disorders).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Fibrodysplasia Ossificans Progressiva (Musculoskeletal Disorders) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

TABLE OF CONTENTS

Introduction
Global Markets Direct Report Coverage
Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Overview
Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Companies Involved in Therapeutics Development
AstraZeneca Plc
BioCryst Pharmaceuticals Inc
Clementia Pharmaceuticals Inc
Daiichi Sankyo Co Ltd
Ipsen SA
Keros Therapeutics Inc
La Jolla Pharmaceutical Company
Oncodesign SA
Pfizer Inc
Regeneron Pharmaceuticals Inc
Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Drug Profiles
Antibody to Antagonize ALK2 for Fibrodysplasia Ossificans Progressiva - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BCX-9250 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BCX-9499 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BLU-782 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dipyridamole - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug for Fibrodysplasia Ossificans Progressiva - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
garetosmab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
KER-047 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
palovarotene - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
saracatinib difumarate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
sirolimus - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule 1 To Inhibit ALK2 for Fibrodysplasia Ossificans Progressiva - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule 2 To Inhibit ALK2 for Fibrodysplasia Ossificans Progressiva - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Activin Receptor-Like Kinase 2 for fibrodysplasia ossificans progressiva - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit ALK2 for Fibrodysplasia Ossificans Progressiva - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
trevogrumab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Dormant Projects
Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Product Development Milestones
Featured News & Press Releases
Dec 09, 2019: Ipsen initiates partial clinical hold for palovarotene IND120181 and IND135403 studies
Nov 04, 2019: BioCryst launches trial to treat fibrodysplasia ossificans progressiva
Oct 24, 2019: Oncodesign: publication of an article presenting promising results for the treatment of stone man syndrome (FOP)
Mar 27, 2019: Blueprint Medicines provides update on clinical progress of BLU-782
Feb 11, 2019: Clementia granted Rare Pediatric Disease Designation by FDA for Palovarotene for Fibrodysplasia Ossificans Progressiva
Oct 23, 2018: Clementia announces plan to submit a new drug application for Palovarotene for the treatment of FOP based on positive phase 2 results
Oct 02, 2018: Clementia initiates phase 1 clinical trial of palovarotene eye drop formulation in healthy volunteers
Oct 01, 2018: Blueprint Medicines presents foundational preclinical data supporting the development of BLU-782, a highly selective ALK2 Inhibitor, for the treatment of patients with fibrodysplasia ossificans progressiva
Sep 26, 2018: Clementia announces updated phase 2 part B data on Palovarotene for FOP
Sep 24, 2018: Blueprint Medicines to present data on BLU-782 at 2018 ASBMR annual meeting
Sep 05, 2018: Clementia to Present at ASBMR 2018 and Upcoming Investor Conferences
Aug 17, 2018: Clementia completes patient enrolment in phase 3 of MOVE Trial
May 23, 2018: Clementia Reports Positive Phase 2 Part B Data Showing Treatment with Palovarotene Significantly Reduces New Bone Growth in Patients with FOP
Jan 05, 2018: BioCryst Advancing Potential Treatment for Rare and Severely Debilitating Fibrodysplasia Ossificans Progressiva
Jan 05, 2018: BioCryst Provides Update on Drug Candidate BCX9499
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

Number of Products under Development for Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva), H2 2019
Number of Products under Development by Companies, H2 2019
Number of Products under Development by Universities/Institutes, H2 2019
Products under Development by Companies, H2 2019
Products under Development by Universities/Institutes, H2 2019
Number of Products by Stage and Target, H2 2019
Number of Products by Stage and Mechanism of Action, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Pipeline by AstraZeneca Plc, H2 2019
Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Pipeline by BioCryst Pharmaceuticals Inc, H2 2019
Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Pipeline by Clementia Pharmaceuticals Inc, H2 2019
Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Pipeline by Daiichi Sankyo Co Ltd, H2 2019
Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Pipeline by Ipsen SA, H2 2019
Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Pipeline by Keros Therapeutics Inc, H2 2019
Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Pipeline by La Jolla Pharmaceutical Company, H2 2019
Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Pipeline by Oncodesign SA, H2 2019
Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Pipeline by Pfizer Inc, H2 2019
Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Pipeline by Regeneron Pharmaceuticals Inc, H2 2019
Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Dormant Projects, H2 2019

List Of Figures

RELATED REPORTS

Fill The Form For Sample Request

Full Name*

Business Email *

E-mail

Country *

Contact No *

Alternate No

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

REVIEWS

There is no Reviews available

Search and Get the Latest Market Research Reports

Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Pipeline Review, H2 2019

Fibrodysplasia ossificans progressiva - Pipeline Insight, 2021

Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Pipeline Review, H1 2020

Fibrodysplasia ossificans progressiva - Pipeline Insight, 2021

Fibrodysplasia Ossificans Progressiva (Myositis Ossificans Progressiva) - Pipeline Review, H1 2020

FAQs